



odimma
Active Personalized Immunotherapy

Opportunity



21.7 million new cancer cases
and **13 million cancer deaths** by 2030



Impressive clinical results with checkpoint
blockers
but only for **20% of patients**



Higher efficacy expected in combination
with **Active Immunotherapies**



Innovative Powerful Personalized Immunization Platform


Global Cancer Vaccine Market

\$ 13 Bn

by 2023
CAGR


17,7%

Active Personalized Immunotherapy



*ICI: Immune Checkpoint Inhibitors

Innovative Powerful Platform




Key differentiator: Combination of 3 important immune players

Competitive Positioning

15 companies worldwide in personalized vaccines
Ranging from **Preclinical** to most advanced **Phase I/II**.



	SYNTHETIC PEPTIDE BASED VACCINES	RNA BASED VACCINES	VIRAL VECTORS	
IMMUNOGENICITY	weak and transient	strong but fast degradation	strong but can limit effective delivery	STRONG*
MANUFACTURING	simple	complex	complex	SIMPLE
COST	low	intermediate	high	LOW
TIME TO DELIVERY	fast	long	long	FAST

*Strong immunity and efficacy obtained in tumor-bearing model (not published yet)



contact@odimma.fr

